Literature DB >> 3866409

Effects of salsalate (nonacetylated salicylate) and aspirin on serum prostaglandins in humans.

H G Morris, N A Sherman, C McQuain, M B Goldlust, S F Chang, L I Harrison.   

Abstract

Prostaglandin E2 (PGE2), thromboxane B2 (TXB2), and salicylic acid were measured in blood samples from 10 healthy men after administration of antiinflammatory doses of aspirin (3.9 g/day) or salsalate (3.0 g/day). Each medication was given for 3 days, followed by an observation period of 13 days. Plasma salicylate concentrations were slightly, but generally insignificantly, higher during aspirin dosing, although both drugs produced salicylic acid levels in the antiinflammatory range. Serum levels of PGE2 and TXB2, which reflected synthesis of cyclo-oxygenase products by platelets, were minimally affected by salsalate but profoundly suppressed by aspirin. When medication was discontinued, the effects of salsalate on serum PGE2 and TXB2 were readily reversible within 36 h, whereas the recovery from aspirin was still incomplete after 13 days of observation. These results indicate that the two orally administered salicylates have differential effects on prostaglandin synthesis in platelets and may also differ in their therapeutic and adverse effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3866409     DOI: 10.1097/00007691-198512000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  13 in total

Review 1.  Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

Authors:  Allison B Goldfine; Steven E Shoelson
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

Review 2.  Safety considerations in treating concomitant diseases in patients with asthma.

Authors:  L W Hunt
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

Review 3.  Salicylates revisited. Are they still the hallmark of anti-inflammatory therapy?

Authors:  S H Roth
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

4.  Salicylsalicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin. An endoscopic comparison.

Authors:  J M Scheiman; E M Behler; R R Berardi; G H Elta
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

5.  Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes.

Authors:  Wen Liang; Lars Verschuren; Petra Mulder; José W A van der Hoorn; Joanne Verheij; Andrea D van Dam; Mariette R Boon; Hans M G Princen; Louis M Havekes; Robert Kleemann; Anita M van den Hoek
Journal:  Br J Pharmacol       Date:  2015-10-22       Impact factor: 8.739

6.  Clinical management of dying patients.

Authors:  J Gavrin; C R Chapman
Journal:  West J Med       Date:  1995-09

7.  Pathogenesis of inflammation. Effects of the pharmacological manipulation of arachidonic acid metabolism on the cytological response to inflammatory stimuli.

Authors:  G Weissmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.

Authors:  Allison B Goldfine; Vivian Fonseca; Kathleen A Jablonski; Laura Pyle; Myrlene A Staten; Steven E Shoelson
Journal:  Ann Intern Med       Date:  2010-03-16       Impact factor: 25.391

Review 9.  Differential analgesic effects of aspirin-like drugs.

Authors:  K Brune; S Menzel-Soglowek; H U Zeilhofer
Journal:  Drugs       Date:  1992       Impact factor: 9.546

10.  Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.

Authors:  Allison B Goldfine; Vivian Fonseca; Kathleen A Jablonski; Yii-Der Ida Chen; Laura Tipton; Myrlene A Staten; Steven E Shoelson
Journal:  Ann Intern Med       Date:  2013-07-02       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.